UPDATE: Endo Tops Q4 Views

reported better-than-expected earnings for the fourth quarter. The Dublin, Ireland-based company reported a quarterly loss of $53.5 million, or $0.35 per share, versus a year-ago net loss of $776 million, or $6.74 per share. Excluding one-time items, the company earned $1.16 per share. Its revenue surged 36.8% to $800 million. However, analysts were estimating earnings of $1.12 per share on revenue of $788 million. U.S. branded pharmaceutical revenue slipped 3% to $246 million in the quarter, while U.S. generic product net sales climbed 70% to $337 million. The International Pharmaceuticals segment posted sales of $79.7 million during the quarter, while device sales rose to $137 million from $132 million. "We are proud of the progress Endo made in rebuilding our business in 2014. This was achieved through multiple strategic transactions, a focus on organic growth and building our R&D pipeline. These efforts, along with the announcement that we will divest our AMS Men's Health and Prostate Health businesses, have helped us continue to transform the company into a leading global specialty pharmaceuticals company and, in the process, deliver strong financial performance," said Rajiv De Silva, President and CEO of Endo. For the full year, Endo projects adjusted earnings of $4.35 to $4.55 per share, on revenue of $2.9 billion to $3 billion. Endo also announced the divestiture of American Medical Systems' Men's And Prostate Health businesses to

for up to $1.65 billion. Endo shares gained 1.05% to $86.50 in pre-market trading.